

Edplin

Customer No. 22,852 Attorney Docket No. 02481.1702

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re A	application of:)
Berny	vard SCHÖLKENS et al.) Group Art Unit: 1617
Applic	ation No.: 09/645,556) Examiner: M. Bahar
Filed:	August 25, 2000))
For:	PHARMACEUTICAL FORMULATIONS AND USE THEREOF IN THE PREVENTION OF STROKE, DIABETES AND/OR CONGESTIVE HEART FAILURE))))
P.O. E	nissioner for Patents Box 1450 ndria, VA 22313-1450	

Sir:

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(c), Applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed after the events recited in Section 1.97(b) but, to the undersigned's knowledge, before the mailing date of either a Final action, Quayle action, or a Notice of Allowance. Under the provisions of 37 C.F.R. § 1.97(c), this Information Disclosure Statement is accompanied by a fee of \$180.00 as specified by Section 1.17(p).

Copies of the listed documents are attached.

10/14/2003 LWONDIM1 00000062 09645556

01 FC:1806

180.00 OP

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	02481.1702	Appln. No.	09/645,556	OIPE
Applicant	Bernard SCHÖLKENS et al.			net 0 9 2003 &
Filing Date	August 25, 2000	Group:	1617	P. S.

		U.S. PATENT	DOCUMENTS			FRADEMA
Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate

	FOREIGN PATE	NT DOCUMENT	S		
Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
-					

Marc A. Pfeffer, MD, PhD et al., "The continuation of the Prevention of Events With Angiotensin-Converting Enzyme Inhibition (PEACE) Trail," American Heart Journal, Vol. 142, Number 3, pp. 375 377, September 2001 Marc A. Pfeffer, MD, PhD et al., "Prevention of Events With Angiotensin-Converting Enzyme Inhibition (The PEACE Study Design), The American Journal of Cardiology, Vol. 82 (3A), pp. 25H-30H, August 6, 1998 The Hope Study Investigators, "The HOPE (Heart Outcomes Prevention Evaluation Study: The design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events," The Canadian Journal of Cardiology Vol. 12, No. 2, pp. 127-137, February 1996	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
Inhibition (The PEACE Study Design), The American Journal of Cardiology, Vol. 82 (3A), pp. 25H-30H, August 6, 1998 The Hope Study Investigators, "The HOPE (Heart Outcomes Prevention Evaluation Study: The design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events," The Canadian Journal of Cardiology	Converting Enzyme Inhibition (PEACE) Trail," American Heart Journal, Vol. 142, Number 3, pp. 33					
design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events," The Canadian Journal of Cardiology		Inhibition (The PEACE Study Design), The American Journal of Cardiology, Vol. 82 (3A), pp. 25H-				
		The Hope Study Investigators, "The HOPE (Heart Outcomes Prevention Evaluation Study: The design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events," The Canadian Journal of Cardiology, Vol. 12, No. 2, pp. 127-137, February 1996				

Examiner	Date Considered
*Examiner:	Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
Form PTO 144	Patent and Trademark Office - U.S. Department of Commerce